RxDoctor Payments Data

Ronald Grossman, MD

Internal Medicine · New York, NYNPI 1720114853

Payments from drug & device makers

$37,986in general payments, 2019–2025

Across 114 payments — averaging $333.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$27K
  • Viiv Healthcare Company$6K
  • Napo Pharmaceuticals Inc$4K
  • Johnson & Johnson$364
  • Theratechnologies Inc.$186
  • Lilly USA, LLC$58
  • plus $252 from 8 others

What the payments were for

  • Consulting fees$5,52015%
  • Speaking & faculty fees$25,63067%
  • Travel & lodging$3,86110%
  • Food & beverage$2,9248%
  • Education$510%

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,986 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$9,748
Medicare patients
28
Services billed
72

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala98$363,867
JulucaDolutegravir/Rilpivirine12$44,930
OdefseyEmtricitab/Rilpiviri/Tenof Ala11$39,916
DescovyEmtricitabine/Tenofov Alafenam18$39,739
PrezcobixDarunavir/Cobicistat15$37,043
TivicayDolutegravir Sodium13$26,796
EvotazAtazanavir Sulfate/Cobicistat13$19,057
EdurantRilpivirine Hcl13$17,225
EliquisApixaban22$17,127
Bevespi AerosphereGlycopyrrolate/Formoterol Fum15$6,506
VascepaIcosapent Ethyl15$5,882
GemtesaVibegron12$5,858
Febuxostat26$1,632
Nebivolol Hcl28$1,630
ValacyclovirValacyclovir Hcl24$1,270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$27,333$403,606116 claims
Viiv Healthcare CompanyJuluca, Tivicay$6,279$71,72625 claims
Johnson & JohnsonPrezcobix$364$37,04315 claims
AstraZenecaBevespi Aerosphere$18$6,50615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →